Clinical Trials Logo

Solid Tumor clinical trials

View clinical trials related to Solid Tumor.

Filter by:

NCT ID: NCT03782467 Completed - Neoplasms Clinical Trials

Phase 1 Study in Patients With Advanced and/or Refractory Solid Malignancies to Evaluate the Safety of ATOR-1015

Start date: January 30, 2019
Phase: Phase 1
Study type: Interventional

The aim of the study is to investigate the safety and tolerability of ATOR-1015 when administered as repeated intravenous infusions to patients with advanced and/or refractory solid malignancies.

NCT ID: NCT03758781 Completed - Clinical trials for Non-Small Cell Lung Cancer

IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors

Start date: February 13, 2019
Phase: Phase 1
Study type: Interventional

This study is to determine the safety of IRX-2 Regimen combined with Nivolumab in patients with recurrent metastatic solid tumors. Researchers believe that this combination will have a tolerable safety profile and will increase the response rate in comparison to Nivolumab alone.

NCT ID: NCT03733587 Completed - Solid Tumor Clinical Trials

GX-I7 With Cyclophosphamide in Patients With Metastatic or Recurrent Solid Tumors

Start date: October 17, 2018
Phase: Phase 1
Study type: Interventional

This is a Phase 1b study to explore the safety and efficacy of GX-I7 in combination with CPA in patients with metastatic or recurrent solid tumors.

NCT ID: NCT03718091 Completed - Solid Tumor Clinical Trials

M6620 (VX-970) in Selected Solid Tumors

Start date: January 8, 2019
Phase: Phase 2
Study type: Interventional

This research study is studying a drug called M6620 as a possible treatment for advanced solid tumor.

NCT ID: NCT03712423 Completed - Solid Tumor Clinical Trials

PET Study With [89Zr]-Df-CriPec® Docetaxel

Start date: April 1, 2018
Phase: Phase 1
Study type: Interventional

A clinical phase I, open-label PET study with [89Zr]-Df-CriPec® docetaxel in patients with solid tumours to assess biodistribution and tumour accumulation of [89Zr]-Df-CriPec® docetaxel.

NCT ID: NCT03707808 Completed - Solid Tumor Clinical Trials

Intratumoral Injection of Autologous CD1c (BDCA-1)+ myDC, Avelumab, and Ipilimumab Plus Systemic Nivolumab

myDAvIpNi
Start date: January 29, 2018
Phase: Phase 1
Study type: Interventional

This phase I trial aims at investigating a new combinatorial immunotherapy regimen using intratumoral injection of autologous CD1c (BDCA-1)+ myeloid dendritic cells in combination with intratumoral injection of the CTLA-4 blocking monoclonal antibody (mAb) ipilimumab and the PD-L1 blocking mAb avelumab. Concomitantly, nivolumab (a PD-1 blocking mAb) will be administered intravenously.

NCT ID: NCT03654716 Completed - Lymphoma Clinical Trials

Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer

Start date: November 1, 2018
Phase: Phase 1
Study type: Interventional

This research study is studying a novel drug called ALRN-6924 as a possible treatment for resistant (refractory) solid tumor, brain tumor, lymphoma or leukemia. The drugs involved in this study are: - ALRN-6924 - Cytarabine (for patients with leukemia only)

NCT ID: NCT03644056 Completed - Solid Tumor Clinical Trials

Dose-escalation Study of IMC-001 in Subject With Metastatic or Locally-advanced Solid Tumors

Start date: March 22, 2018
Phase: Phase 1
Study type: Interventional

This is a phase 1, Open-label, Multiple-ascending Dose Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of IMC-001 in Subjects with Metastatic or Locally-advanced Solid Tumors

NCT ID: NCT03642834 Completed - Solid Tumor Clinical Trials

Study of ICP-105 in Solid Tumors Patients

Start date: September 21, 2018
Phase: Phase 1
Study type: Interventional

Open-label, non-randomized, Phase I, dose-escalating, first-in-man study.

NCT ID: NCT03641547 Completed - Solid Tumor Clinical Trials

M6620 Plus Standard Treatment in Oesophageal and Other Cancer

CHARIOT
Start date: December 4, 2018
Phase: Phase 1
Study type: Interventional

This Phase I study will test the combination of a novel ATR inhibitor (M6620) with chemoradiotherapy in oesophageal cancer; utilizing three experimental cohorts (Stage A1, A2 and B).